Amivantamab for previously treated, locally advanced or metastatic EGFR exon 19 deletion or exon 21 L858R substitution mutation-positive non-small-cell lung cancer

Published on 06 Feb 2026
Last Updated on 06 Feb 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended amivantamab, in combination with platinum-based chemotherapy, for inclusion on the MOH List of Subsidised Drugs for previously treated, locally advanced or metastatic epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation-positive non-small-cell lung cancer. The decision was based on the uncertain extent of clinical benefit, unfavourable cost-effectiveness compared with platinum-based chemotherapy, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for amivantamab are provided in the Annex.

Guidance_Amivantamab for previously treated, locally advanced or metastatic EGFR exon 19 deletion or exon 21 L858R substitution mutation-positive non-small-cell lung cancer (6 Feb 2026)

PES_Amivantamab for treating EFGR mutation-positive non-small-cell lung cancer (6 Feb 2026)